Laurent Fischer - 29 May 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
29 May 2025
Net transactions value
$0
Form type
4
Filing time
02 Jun 2025, 19:33:03 UTC
Previous filing
16 May 2025
Next filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Fischer Laurent Director C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY /s/ Judit Ryvkin, Attorney-in-Fact 02 Jun 2025 0001379344

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Award $0 +6,268 $0.000000 6,268 29 May 2025 Common Stock 6,268 $44.00 Direct F1
transaction MIRM Restricted Stock Units Award $0 +3,977 $0.000000 3,977 29 May 2025 Common Stock 3,977 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2026 annual stockholder meeting.